Literature DB >> 11129227

Predominant T helper 1 cells in patients with idiopathic portal hypertension.

K Tokushige1, K Yamauchi, T Komatsu, K Takasaki, N Hayashi.   

Abstract

BACKGROUND: The pathologic mechanism of idiopathic portal hypertension (IPH) is unknown. Because cytokines and the balance of T helper (h) 1 and Th2 CD4+ T cells have been reported to be important for regulating the immune response, in the present study we investigated the role of cytokines and the distribution of cytokine-producing cells in IPH patients.
METHODS: Serum levels of tumor necrosis factor (TNF)-alpha, soluble TNF receptor-I, -II, interferon (IFN)-gamma and interleukin (IL)-4 were measured in IPH patients, fatty liver patients, chronic hepatitis patients and control subjects. The percentages of Th0, Th1 and Th2 CD4+ T cells were examined in peripheral and spleen lymphocytes in IPH patients by intracellular staining.
RESULTS: Serum levels of TNF-alpha, soluble TNF receptor-I, interferon-gamma and IL-4 of IPH patients were not increased in comparison with control subjects. Only the mean value of soluble TNF receptor-II was significantly higher than that of control subjects and fatty liver patients. The ratios of Th1 and Th2 in both peripheral and spleen lymphocytes of IPH patients were significantly increased compared with the ratios found in peripheral lymphocytes of control subjects. The increase in the ratios was due to a decrease in the percentage of Th2 CD4+ T cells.
CONCLUSIONS: These results suggest that the imbalance of Th1 and Th2 CD4+ T cells and TNF may be associated with the pathogenesis of IPH.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11129227

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

Review 1.  Portal hypertensive gastropathy and gastric antral vascular ectasia (GAVE) syndrome.

Authors:  K W Burak; S S Lee; P L Beck
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

2.  Induction of elastin expression in vascular endothelial cells relates to hepatoportal sclerosis in idiopathic portal hypertension: possible link to serum anti-endothelial cell antibodies.

Authors:  Y Sato; X S Ren; K Harada; M Sasaki; H Morikawa; S Shiomi; M Honda; S Kaneko; Y Nakanuma
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

3.  Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment.

Authors:  Shiv Kumar Sarin; Ashish Kumar; Yogesh Kumar Chawla; Sanjay Saran Baijal; Radha Krishna Dhiman; Wasim Jafri; Laurentius A Lesmana; Debendranath Guha Mazumder; Masao Omata; Huma Qureshi; Rizvi Moattar Raza; Peush Sahni; Puja Sakhuja; Mohammad Salih; Amal Santra; Barjesh Chander Sharma; Praveen Sharma; Gamal Shiha; Jose Sollano
Journal:  Hepatol Int       Date:  2007-09-11       Impact factor: 6.047

4.  Clinical features, serum interleukin-6, and interferon-gamma levels of 34 turkish patients with hepatoportal sclerosis.

Authors:  Aydin Seref Köksal; Seyfettin Köklü; Mehmet Ibiş; Mustafa Balci; Bahattin Ciçek; Nurgül Saşmaz; Burhan Sahin
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.199

Review 5.  Portal hypertension as immune mediate disease.

Authors:  Sara Manti; Lucia Marseglia; Gabriella D'Angelo; Martina Filippelli; Caterina Cuppari; Eloisa Gitto; Claudio Romano; Teresa Arrigo; Carmelo Salpietro
Journal:  Hepat Mon       Date:  2014-06-07       Impact factor: 0.660

6.  Comprehensive Screening of Gene Function and Networks by DNA Microarray Analysis in Japanese Patients with Idiopathic Portal Hypertension.

Authors:  Kohei Kotani; Joji Kawabe; Hiroyasu Morikawa; Tomohiko Akahoshi; Makoto Hashizume; Susumu Shiomi
Journal:  Mediators Inflamm       Date:  2015-10-04       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.